2nd generation EGFR TKI Vizimpro can be prescribed in Big 5

Competition with Giotrif, the same second-generation non-small cell lung cancer treatment, is expected

Pfizer's second-generation EGFR TKI Vizimpro has settled in the Big 5 General Hospital.

 

According to related industries, Pfizer's EGFR TKI Vizimpro recently passed all five major medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St.

 

Mary's Hospital, Asan Medical Center, and Sinchon Severance Hospital.

 

It was completed at major medical institutions nationwide, including the National Cancer Center, Seoul National University Bundang Hospital, Pusan National University Hospital, Chungbuk National University Hospital, and Chungnam National University Hospital.

 

Vizimpro, which was listed on the insurance benefit list in December 2021, was designated as a priority review target by the US FDA in January 2018 and approved in September of the same year.

 

Currently, it is licensed and used in the United States, the European Union, and Japan.

 

In Korea, Vizimpro was approved as the first treatment for local progressive or metastatic EGFR mutation non-small cell lung cancer in February last year.

 

VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung canker (NSCLC) with epidermal growth factor acceptor (EGFR) exection 19 deployment measurement 2185 or 85.

 

Currently, EGFR TKI such as AstraZeneca's Iressa, the first-generation drug, Roche's Tarceva, AstraZeneca's Tagrisso, and Yuhan's Leclaza are prescribed in Korea.

 

Competition to attract prescriptions for Giotrif and Vizimpro, the second-generation drugs, is expected to intensify in the future.

 

The efficacy of Vizimpro has been demonstrated through ARCHER 1050, a phase 3 clinical trial.

 

The study directly compared Vizimpro with Iressa, the first-generation drug, and a total of 452 non-small cell lung cancer patients were registered.

 

Progression-Free Survival (PFS) reduced the risk ratio by 41% compared to Iressa, and the median PFS value was 14.7 months for Vizimpro, ahead of the Iressa administration group of 9.2 months.

 

The results of the side effects of Vizimpro were poor.

 

The common severe side effects of Grade 3 or higher were 14% acne and 8% diarrhea in the Vizimpro administration group, and 8% liver enzyme abnormalities occurred in the Iressa administration group.

 

60% of the Vizimpro administration group needed dose adjustment as a side effect.